Breaking News From Pharma & Bio Ingredients
Crucell and Merck Sign Deal on Vaccines
Posted on 2006-12-27 10:43:00
Dutch biotechnology company Crucell N.V. on Wednesday announced it had signed a cross-licensing agreement with Merck & Co, Inc.
Under the deal, Merck will be allowed to use Crucell technology on an exclusive basis in undisclosed vaccine fields. In return Crucell will receive access to Merck's large-scale manufacturing technology for its AdVac-based malaria and TB vaccines. The financial terms of the deal weren't disclosed.
Subscribe via RSS
